Part of: The Anatomy of an FDA Warning Letter
TL;DR
- Some Warning Letter citations explicitly flag that a finding is a repeat of a prior inspection's citation — CDRH's June 2026 letter to BlephEx, LLC cites one violation as "a repeat of a 2019 citation," a direct example of this language appearing in a real letter.
- A repeat finding is a materially worse fact pattern than a first-time citation of the same issue: it demonstrates the company was already on notice and either failed to implement an effective fix or implemented one that didn't hold.
- Repeat findings often correlate with harsher outcomes in the same letter — the BlephEx letter combined the repeat citation with FDA's rejection of six consecutive prior company responses.
- Spotting repeat-finding language requires reading the citation section closely for explicit references to prior inspection years or prior citation numbers, since not every citation section flags a repeat as clearly as the BlephEx example does.
Why repeat findings carry more weight than the citation count alone suggests
A Warning Letter with seven cited violations reads, on a simple headline basis, as more severe than one with three. But citation count alone misses a more important signal: whether any of the cited violations are new problems FDA is identifying for the first time, or whether they're violations the company was already told about — sometimes years earlier — that still haven't been resolved. A repeat finding changes the character of the underlying compliance failure from "we missed something" to "we were told about this and it's still happening," a materially worse narrative for any subsequent enforcement decision or litigation.
The BlephEx example, in detail
CDRH's June 2026 Warning Letter to BlephEx, LLC cites seven separate Quality System Regulation violations. One of those seven is explicitly flagged as "a repeat of a 2019 citation" (Argus HQ, "Why Did FDA Reject BlephEx's Quality Fixes Six Times?"). That single phrase does a lot of work: it tells the reader this isn't the company's first encounter with this specific issue, that a prior inspection (in 2019) already identified it, and that whatever the company did in response — if anything — either wasn't implemented, wasn't sustained, or wasn't effective.
The BlephEx letter is also notable for a second reason that compounds the repeat-finding signal: FDA rejected six consecutive company responses in a row before issuing the Warning Letter, on findings that included marketing three ophthalmic devices beyond their cleared use and an unreported charger correction after a handpiece "blew up" in use. Read together, the repeat citation and the six rejected responses paint a consistent picture: a company whose corrective-action process, across multiple attempts and multiple years, wasn't producing fixes that satisfied FDA.
Why repeat findings tend to correlate with harsher outcomes
FDA's Section 4 company-response assessment — the part of a Warning Letter (or a rejection of a prior response) that evaluates whether corrective actions are adequate — has direct visibility into a company's response history at a given facility. A citation that's explicitly flagged as a repeat is, by definition, one where FDA already has a documented history of the company's prior response (or lack of one) to draw on. That history makes it harder for a company to argue the current finding reflects an isolated oversight, and easier for FDA to treat the current letter's tone and remedy expectations as calibrated to a demonstrated pattern rather than a first encounter.
How to spot repeat-finding language when it isn't as explicit as BlephEx's
Not every citation section flags a repeat as directly as "a repeat of a 2019 citation." Readers should watch for several related but less explicit signals: a citation section referencing a specific prior inspection date or prior Form 483 observation by number; language noting that "similar findings were observed during the previous inspection"; or a Section 4 company-response discussion that references a specific corrective action plan the company submitted after an earlier inspection, followed by a note that the same or a related deficiency persisted. Any of these patterns functions the same way as an explicit "repeat" label — they establish that FDA is treating the current finding in the context of the facility's documented history, not as a fresh, first-encounter observation.
What a repeat finding should trigger internally
A company that receives a Warning Letter with a repeat-finding citation should treat the internal response differently from how it would treat a genuinely first-time finding. The remediation plan needs to explicitly address why the prior corrective action (if one was submitted) didn't hold, not just restate a new version of the same fix that already failed once. A remediation plan that doesn't account for why the earlier fix didn't work is vulnerable to the same rejection pattern documented in the BlephEx letter's six consecutive rejected responses — FDA has already shown, in that specific case, a willingness to reject multiple successive submissions rather than accept a plan that doesn't convincingly address why the problem recurred.
What this means for reading any Warning Letter's citation section
- Read every citation for explicit or implicit references to prior inspections, not just the current findings in isolation. A repeat finding changes the severity calculus even when the citation count itself looks moderate.
- Treat a repeat finding as evidence the prior response failed, not just as a second instance of the same problem. The remediation plan needs to address why the earlier fix didn't hold, not simply propose a similar fix again.
- Multiple rejected responses and repeat findings tend to appear together. The BlephEx pattern — a repeat citation alongside six rejected prior responses — suggests these two signals often reflect the same underlying dynamic: a corrective-action process that isn't producing durable fixes.
- Watch for less explicit repeat-finding signals, not just the word "repeat" itself. References to prior inspection dates, prior Form 483 observations, or a Section 4 discussion of an earlier corrective action plan all function the same way even without the word appearing directly.
Related reading
- The Anatomy of an FDA Warning Letter — the pillar this spoke expands on.
- Why Did FDA Reject BlephEx's Quality Fixes Six Times? — the underlying case discussed above, in full.
- The Boilerplate Paragraphs Every FDA Warning Letter Shares — the companion spoke on the future-inspection language that makes repeat findings possible in the first place.
Sources
- Argus HQ, Why Did FDA Reject BlephEx's Quality Fixes Six Times? — source of the "repeat of a 2019 citation" language and the six-rejected-responses detail.
Argus HQ is informational only. Summaries are AI-assisted and may contain errors, misclassifications, or omissions. The underlying FDA Warning Letters are public records; always verify against the original source before regulatory decisions. Not legal, financial, or medical advice.